One of the Yerkes Research Center’s foremost scientific goals is the development of an AIDS vaccine that will help end the global epidemic now affecting more than 42 million people. An HIV/AIDS vaccine Yerkes researchers developed to prevent progression to the disease is in Phase 2a clinical trials. The FDA recently granted allowance for that vaccine, now licensed to GeoVax Labs, Inc., to be used in a Phase 1 clinical trial as a treatment for individuals infected with HIV.






